Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.

@article{Suda2011EpithelialTM,
  title={Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.},
  author={Kenichi Suda and Kenji Tomizawa and Makiko Fujii and Hideki Murakami and Hirotaka Osada and Yoshihiko Maehara and Yasushi Yatabe and Yoshitaka S Sekido and Tetsuya Mitsudomi},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2011},
  volume={6 7},
  pages={1152-61}
}
INTRODUCTION Mesenchymal status is related to "inherent resistance" to gefitinib or erlotinib in non-small cell lung cancer without epidermal growth factor receptor(EGFR) mutations. In addition, a recent report showed that the epithelial to mesenchymal transition (EMT) plays a role in acquired resistance to gefitinib in A549 cells, which harbor a KRAS mutation. However, recent clinical studies revealed that gefitinib or erlotinib are highly effective in the treatment of non-small cell lung… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 115 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Similar Papers

Loading similar papers…